Tag: MONOGRAPH

  • Anastrozole

    Plain-language summaryIntrigue 65 / 100

    Anastrozole (Arimidex) is a third-generation aromatase inhibitor approved in 1995, first-line for postmenopausal hormone-receptor-positive breast cancer. It blocks the aromatase enzyme, which converts androgens (including testosterone) into estrogens. At the standard 1 mg daily dose, it lowers plasma estradiol by about 80 percent. In breast cancer this slows or shrinks estrogen-driven tumors. Off-label, low doses are used by anabolic steroid users to control estrogen conversion and prevent gynecomastia. Side effects include joint stiffness and accelerated bone loss (because estrogen is essential for bone in both sexes). The ATAC trial established its superiority over tamoxifen in postmenopausal women. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Third-generation nonsteroidal aromatase inhibitor (triazole derivative)

    A potent, selective, reversible nonsteroidal aromatase inhibitor developed at Zeneca Pharmaceuticals for the adjuvant treatment of estrogen receptor-positive breast cancer, distinguished from steroidal inactivators by triazole-mediated competitive binding, oral bioavailability, and a long terminal half-life permitting once-daily dosing.

    Abstract

    Anastrozole (ZD1033, Arimidex) is a third-generation nonsteroidal aromatase inhibitor of the triazole class that selectively and reversibly inhibits the cytochrome P450 19A1 (CYP19A1, aromatase) enzyme complex responsible for the terminal step in estrogen biosynthesis: the conversion of androstenedione to estrone and testosterone to estradiol. At the approved oral dose of 1 mg once daily, anastrozole achieves greater than 96 percent suppression of plasma estradiol in postmenopausal women and approximately 97 percent inhibition of whole-body aromatase activity, without measurable effects on adrenocortical steroidogenesis, aldosterone production, or thyroid function. The compound was developed at Zeneca Pharmaceuticals (now AstraZeneca) through systematic optimization of triazole-bearing aromatase inhibitor scaffolds and received United States Food and Drug Administration approval in 1995 for the treatment of advanced breast cancer in postmenopausal women following tamoxifen therapy, with subsequent label expansions to first-line advanced disease (2000) and adjuvant treatment of early-stage hormone receptor-positive breast cancer (2002).

    The pivotal Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, enrolling 9,366 postmenopausal women with early-stage invasive breast cancer, established anastrozole as superior to tamoxifen on disease-free survival, time to recurrence, time to distant recurrence, and incidence of contralateral breast cancer at 100-month and 10-year analyses, with a carryover benefit extending beyond the 5-year treatment period. The International Breast Cancer Intervention Study II (IBIS-II) subsequently demonstrated a 49 percent reduction in breast cancer incidence in high-risk postmenopausal women receiving anastrozole 1 mg daily for 5 years compared to placebo, with a persistent preventive effect beyond the active treatment period at 131 months of median follow-up. Anastrozole is now among the most widely prescribed endocrine therapies in oncology, with established roles in adjuvant, neoadjuvant, extended adjuvant, and chemoprevention settings for estrogen receptor-positive breast cancer.

    Pharmacokinetics are characterized by rapid oral absorption (time to peak concentration approximately 2 hours), high oral bioavailability (approximately 85 percent), extensive hepatic metabolism through N-dealkylation, hydroxylation, and glucuronidation (with a principal inactive triazole metabolite), and a long terminal elimination half-life of 40 to 50 hours that supports once-daily dosing and achieves steady-state plasma concentrations within approximately 7 days. Anastrozole is not a potent inhibitor or inducer of cytochrome P450 enzymes at therapeutic concentrations, and clinically significant drug-drug interactions are uncommon. The compound is well tolerated; the principal adverse events are hot flashes, arthralgia, fatigue, and musculoskeletal stiffness, with the most clinically significant long-term safety signal being accelerated bone mineral density loss and increased fracture risk attributable to profound estrogen suppression, managed in clinical practice through concurrent bisphosphonate therapy and bone density monitoring.

    Beyond the oncology indication, anastrozole has been investigated as an off-label research tool for modulating the hypothalamic-pituitary-gonadal axis in males, where aromatase inhibition reduces the conversion of testosterone to estradiol, relieves estrogen-mediated negative feedback on gonadotropin secretion, and increases endogenous testosterone production. This application remains investigational and is not approved by regulatory authorities. This monograph reviews the chemistry, synthesis, and structural class of anastrozole; the molecular pharmacology of aromatase inhibition; the comprehensive pharmacokinetic record; preclinical pharmacology; the clinical evidence base across adjuvant, neoadjuvant, chemoprevention, and investigational indications; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signals; and a comparative assessment of five alternative aromatase-modulating agents against anastrozole on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-276Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Adamax

    Synthetic melanocortin-derived nootropic peptide with dual N-acetyl and C-terminal adamantane modifications for enhanced blood-brain barrier permeability and neurotrophic factor modulation

    A next-generation ACTH(4-10) analog engineered from Semax with N-terminal acetylation and C-terminal adamantylglycine amidation, designed to extend plasma half-life and central nervous system bioavailability while preserving the parent compound’s neurotrophic, neuroprotective, and monoaminergic pharmacology.

    Abstract

    Adamax (N-Acetyl Semax-Adamantane; Ac-MEHFPGP-AdaGly-NH2) is a synthetic nonapeptide research compound derived from Semax, the Russian-developed ACTH(4-10) analog approved in the Russian Federation for the treatment of ischemic stroke and cognitive impairment. The compound incorporates two structural modifications to the Semax backbone (Met-Glu-His-Phe-Pro-Gly-Pro): an N-terminal acetyl group that shields the peptide from aminopeptidase degradation and a C-terminal adamantylglycine amide that increases lipophilicity, enhances blood-brain barrier penetration, and confers resistance to carboxypeptidase cleavage. These modifications extend the effective half-life from approximately 30 to 60 minutes (Semax) to an estimated 8 to 10 hours and increase central nervous system bioavailability, enabling single daily dosing protocols in research applications.

    The pharmacological rationale for Adamax rests on the established molecular pharmacology of its parent compound Semax and on the broader adamantane medicinal chemistry literature. Semax activates brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB) signaling in the hippocampus and basal forebrain, modulates melanocortin-3 and melanocortin-4 receptor (MC3R/MC4R) activity in cortical and hypothalamic circuits, and enhances dopaminergic and serotonergic neurotransmission in the striatum and prefrontal cortex [1, 2, 3]. Adamax preserves this multi-target pharmacology while the adamantane cage, a rigid tricyclo[3.3.1.1(3,7)]decane hydrocarbon scaffold shared with the FDA-approved drugs amantadine and memantine, confers the lipophilicity necessary for passive transcellular blood-brain barrier transit and reduces the susceptibility of the C-terminus to exopeptidase degradation [4, 5].

    Adamax does not have independent, peer-reviewed clinical or preclinical pharmacology publications indexed in PubMed or comparable biomedical databases as of the date of this monograph. All mechanistic characterization is inferred from the extensive published literature on Semax (over 300 publications, predominantly in Russian-language journals with a growing English-language subset), from the P21 (P021) adamantane-modified neurotrophic peptide literature, and from the structure-activity relationships of the ACTH(4-10) melanocortin fragment class. The compound is sold as a research-grade preparation by multiple peptide suppliers and has been identified as a designer peptide in border seizures by the New Zealand Medicines and Medical Devices Safety Authority [6]. It is not approved by any regulatory agency for therapeutic use. Investigators should treat all pharmacological claims as extrapolations from parent-compound data until independent Adamax-specific studies are published. This monograph reviews the chemistry, structural rationale, inferred mechanism of action, pharmacokinetic considerations, the parent-compound evidence base, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, the safety signal profile, and a comparative assessment of five related nootropic peptide compounds (Semax, N-Acetyl Semax Amidate, P21, Selank, Noopept) against Adamax on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1325Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Amitriptyline

    Plain-language summaryIntrigue 65 / 100

    Amitriptyline (Elavil) is one of the founding tricyclic antidepressants, approved in 1961 and still in heavy clinical use, though almost never for depression anymore. At antidepressant doses (150 to 300 mg) the side-effect burden is rough: heavy sedation, dry mouth, constipation, weight gain, and blood pressure drops on standing. At low doses (10 to 75 mg) it has become a workhorse for chronic pain, particularly neuropathic pain, tension headache, and migraine prevention, where its effects on serotonin and norepinephrine signaling in spinal pain pathways do useful work. It also blocks sodium channels in the heart, which makes overdose genuinely dangerous and limits its use in anyone with cardiac conduction disease. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Tricyclic dibenzocycloheptadiene antidepressant with serotonin-norepinephrine reuptake inhibition and multi-target ion channel modulation

    A first-generation tricyclic antidepressant developed at Merck in the late 1950s, distinguished from later monoamine reuptake inhibitors by broad receptor polypharmacology spanning serotonin and norepinephrine transporters, voltage-gated sodium channels, NMDA receptors, histamine H1, muscarinic acetylcholine, and alpha-1 adrenergic receptors, supporting clinical applications across major depression, neuropathic pain, migraine prophylaxis, fibromyalgia, and irritable bowel syndrome.

    Abstract

    Amitriptyline (3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine) is a first-generation tricyclic antidepressant (TCA) and the second member of the tricyclic class to reach the market, approved by the United States Food and Drug Administration in 1961 for the treatment of major depressive disorder. Originally developed at Merck Sharp and Dohme as a structural analog of imipramine in which the diamine bridge nitrogen is replaced by an exocyclic propylidene chain, amitriptyline inhibits the serotonin transporter (SERT) and norepinephrine transporter (NET) with low-nanomolar affinity for both targets (Ki approximately 3.1 nM for SERT, 19 nM for NET), producing dual monoamine reuptake inhibition that is mechanistically ancestral to the modern selective serotonin-norepinephrine reuptake inhibitors. Amitriptyline is distinguished from the SSRIs and SNRIs, however, by extensive polypharmacology at secondary targets: the compound acts as a potent antagonist at histamine H1 receptors (Ki approximately 1.1 nM), muscarinic acetylcholine receptors (Ki approximately 14 nM), and alpha-1 adrenergic receptors (Ki approximately 24 nM); as a use-dependent blocker of voltage-gated sodium channels through binding at the local anesthetic receptor site; and as an open-channel blocker of NMDA-type glutamate receptors with an IC50 in the low-micromolar range. This composite receptor profile produces the broad clinical utility of amitriptyline but also the anticholinergic, sedative, and cardiovascular adverse-event burden that has driven displacement by narrower-spectrum agents in the primary antidepressant indication.

    Despite the decline of tricyclic antidepressant prescribing for depression in the SSRI era, amitriptyline remains one of the most widely prescribed medications worldwide. The World Health Organization lists amitriptyline on its Model List of Essential Medicines. The compound is a first-line treatment for neuropathic pain in multiple international guidelines (NICE, AAN, NeuPSIG), supported by decades of randomized controlled trial evidence in painful diabetic neuropathy, postherpetic neuralgia, and mixed neuropathic pain syndromes. The 2022 OPTION-DM trial, the largest head-to-head crossover neuropathic pain trial ever conducted, demonstrated equivalent analgesic efficacy of amitriptyline, duloxetine, and pregabalin monotherapy in diabetic peripheral neuropathic pain, with combination therapy producing superior analgesia. The 2023 ATLANTIS trial, the largest randomized controlled trial of a tricyclic antidepressant in irritable bowel syndrome, demonstrated that low-dose titrated amitriptyline (10 to 30 mg daily) was superior to placebo as second-line treatment for IBS in primary care across multiple symptom endpoints at 6 months. Amitriptyline is recommended for migraine prophylaxis (NNT approximately 3 to 4 for 50 percent headache frequency reduction) and for fibromyalgia analgesia, and it retains clinical use in tension-type headache, insomnia comorbid with chronic pain, nocturnal enuresis, and selected anxiety disorders.

    Pharmacokinetics are dominated by hepatic metabolism through two principal cytochrome P450 pathways: CYP2C19-mediated N-demethylation to the active metabolite nortriptyline (itself a potent and selective NET inhibitor) and CYP2D6-mediated hydroxylation to 10-hydroxymetabolites that are subsequently glucuronidated and renally excreted. Both CYP2C19 and CYP2D6 exhibit clinically significant genetic polymorphism. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published dosing guidelines for amitriptyline indexed to CYP2D6 and CYP2C19 genotype, recommending dose reduction or alternative agent selection in CYP2D6 poor metabolizers and CYP2C19 ultrarapid metabolizers. Plasma elimination half-life ranges from 10 to 28 hours across the population; oral bioavailability is approximately 45 percent owing to substantial first-pass hepatic metabolism.

    The compound is well tolerated at the low doses (10 to 50 mg) used for pain and functional gastrointestinal indications but produces dose-dependent anticholinergic (dry mouth, constipation, urinary retention, blurred vision), antihistaminic (sedation, weight gain), and cardiovascular (orthostatic hypotension, tachycardia, QT prolongation, QRS widening) adverse events at the higher doses (100 to 300 mg) used for depression. Amitriptyline has a narrow therapeutic index; ingestion of 10 to 20 mg/kg is potentially life-threatening through sodium channel blockade producing cardiac conduction delay, ventricular dysrhythmias, and myocardial depression. This monograph documents the chemistry, synthesis, and structural class of amitriptyline; the multi-target receptor pharmacology; the comprehensive human pharmacokinetic record including CYP2C19 and CYP2D6 pharmacogenomics; the clinical evidence base across depression, neuropathic pain, migraine, fibromyalgia, irritable bowel syndrome, and other indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal; and a structured comparative assessment of five analgesic alternatives (duloxetine, pregabalin, gabapentin, nortriptyline, desipramine) against amitriptyline on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-216Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Amphetamine

    Plain-language summaryIntrigue 75 / 100

    Amphetamine is the prototype phenethylamine stimulant and the foundational compound for an entire pharmacological class. First synthesized in 1887 and developed clinically as Benzedrine in the 1930s, it works by reversing the transporters that normally pull dopamine, norepinephrine, and serotonin out of the synapse. Instead of inhibiting reuptake, it forces these neurotransmitters to flow outward, raising synaptic levels. Sold as Adderall (mixed salts), Dexedrine, and Evekeo for ADHD and narcolepsy. The two enantiomers behave differently: d-amphetamine is more dopaminergic and CNS-focused, l-amphetamine has stronger peripheral norepinephrine effects. Schedule II in the US with significant abuse potential. The canonical monoamine releaser in pharmacology research and a reference point for nearly every later phenethylamine. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Phenethylamine-class sympathomimetic monoamine-releasing agent with activity at the dopamine transporter, norepinephrine transporter, vesicular monoamine transporter 2, and trace amine-associated receptor 1

    A racemic or enantiopure phenylpropylamine first synthesized in 1887, developed as the prototypical indirect sympathomimetic stimulant, and established as a first-line pharmacotherapy for attention-deficit/hyperactivity disorder and narcolepsy through potent reversal of monoamine transporter function and vesicular monoamine redistribution.

    Abstract

    Amphetamine (alpha-methylphenethylamine) is the prototypical phenethylamine-class sympathomimetic amine and the most extensively characterized indirect monoamine-releasing agent in clinical neuropharmacology. First synthesized by Lazar Edeleanu in 1887 at the University of Berlin and pharmacologically characterized by Gordon Alles in 1927, amphetamine entered clinical medicine in 1933 as the Benzedrine inhaler for nasal congestion and was subsequently developed for narcolepsy, depression, obesity, and, from the 1960s onward, attention-deficit/hyperactivity disorder (ADHD). The compound acts principally by reversing the direction of the plasma membrane dopamine transporter (DAT) and norepinephrine transporter (NET), producing non-exocytotic efflux of cytoplasmic dopamine and norepinephrine into the synaptic cleft; by inhibiting vesicular monoamine transporter 2 (VMAT2), redistributing vesicular monoamine stores into the cytosol; and by activating the intracellular trace amine-associated receptor 1 (TAAR1), which modulates transporter phosphorylation state and downstream signaling cascades. Secondary mechanisms include weak inhibition of monoamine oxidase and modest serotonin transporter (SERT) reversal at higher concentrations. The net pharmacological effect is a robust increase in synaptic dopamine and norepinephrine concentrations in the prefrontal cortex, striatum, and nucleus accumbens, producing the characteristic profile of enhanced attention, executive function, wakefulness, locomotor activation, and appetite suppression.

    Pharmacokinetics are characterized by high oral bioavailability (approximately 75 to 100 percent depending on gastrointestinal pH and formulation), a plasma elimination half-life of approximately 10 hours for dextroamphetamine and 13 hours for levoamphetamine in adults, hepatic metabolism through cytochrome P450 2D6 (CYP2D6) hydroxylation and flavin-containing monooxygenase 3 (FMO3) N-oxidation, and pH-dependent renal excretion of unchanged drug. The two enantiomers exhibit differential potency: dextroamphetamine (the S-enantiomer) is approximately three to five times more potent than levoamphetamine (the R-enantiomer) at dopaminergic targets, while levoamphetamine retains relatively greater noradrenergic potency. Commercial formulations exploit this differential through racemic mixtures (mixed amphetamine salts), enantiopure dextroamphetamine preparations, and the prodrug lisdexamfetamine.

    The clinical evidence base for amphetamine in ADHD is among the largest in psychopharmacology. The 2018 Lancet Psychiatry network meta-analysis of 133 randomized controlled trials encompassing over 10,000 adult participants identified amphetamines as the most efficacious pharmacotherapy for ADHD in adults, with standardized mean differences on core symptom scales exceeding those of methylphenidate, atomoxetine, modafinil, and bupropion. In children and adolescents, amphetamines demonstrated the largest effect sizes on clinician-rated symptom measures among all studied agents. The compound is additionally approved for narcolepsy type 1 and has been investigated in treatment-resistant depression, traumatic brain injury-related cognitive dysfunction, and obesity.

    The safety profile at therapeutic doses is well characterized. Common adverse events include appetite suppression, insomnia, dry mouth, tachycardia, and modest systolic blood pressure elevation. Cardiovascular risk at therapeutic doses in individuals without structural heart disease is low, as demonstrated by multiple large pharmacoepidemiologic cohort studies. The principal long-term concern is the reinforcing properties of amphetamine mediated by mesolimbic dopamine signaling, which confer abuse liability; all amphetamine formulations carry a Schedule II controlled substance classification under the United States Controlled Substances Act. This monograph reviews the chemistry, stereochemistry, and synthesis of amphetamine; the multi-target molecular pharmacology including DAT, NET, VMAT2, and TAAR1 mechanisms; comprehensive pharmacokinetics; preclinical behavioral and neurochemical pharmacology; the clinical evidence base across ADHD, narcolepsy, and investigational indications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signals; and a comparative assessment of five alternative agents (methylphenidate, lisdexamfetamine, atomoxetine, modafinil, guanfacine) against amphetamine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-378Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Agomelatine

    Plain-language summaryIntrigue 68 / 100

    Agomelatine is an antidepressant that combines melatonin receptor activation (sleep regulation) with 5-HT2C antagonism (mood). FDA declined approval; widely used in Europe under the brand Valdoxan. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Melatonergic MT1/MT2 receptor agonist with serotonin 5-HT2C receptor antagonism

    A naphthalenic melatonin analog developed at Servier as the first non-monoaminergic antidepressant, distinguished by dual melatonergic agonism and serotonin 5-HT2C antagonism that resynchronizes disrupted circadian rhythms while enhancing frontocortical dopaminergic and noradrenergic transmission.

    Abstract

    Agomelatine (S 20098) is a naphthalenic analog of melatonin and the first clinically approved antidepressant whose mechanism of action does not rely on direct modulation of monoamine reuptake or degradation. Developed by Servier Laboratories and granted European marketing authorization in 2009 under the trade names Valdoxan and Thymanax, agomelatine acts through high-affinity agonism at the melatonin MT1 and MT2 G-protein-coupled receptors (Ki approximately 0.1 nanomolar) combined with neutral antagonism at the serotonin 5-HT2C receptor (Ki approximately 630 nanomolar), a pharmacological profile that is unique among marketed antidepressants and that produces a synergistic downstream effect on circadian rhythm resynchronization, frontocortical dopamine and norepinephrine release, hippocampal neurogenesis, and brain-derived neurotrophic factor (BDNF) expression. The compound does not bind serotonin transporters, norepinephrine transporters, dopamine transporters, or any of the receptor families (muscarinic, histaminergic, adrenergic, GABAergic, glutamatergic, opioid) that produce the common adverse-event signatures of the selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor, and tricyclic antidepressant classes, and consequently exhibits a tolerability profile characterized by the absence of sexual dysfunction, weight gain, discontinuation syndrome, and serotonin syndrome risk that distinguishes it from essentially all other antidepressant classes.

    Clinical efficacy in major depressive disorder has been established in multiple randomized, double-blind, placebo-controlled trials at the approved oral dose of 25 to 50 mg once daily at bedtime; pooled head-to-head analyses against fluoxetine, sertraline, venlafaxine, paroxetine, and escitalopram demonstrate broadly comparable antidepressant efficacy with superior tolerability and lower dropout rates. Relapse prevention has been demonstrated in a 24-week extension study with significantly lower cumulative relapse rate on agomelatine (24 percent) compared to placebo (50 percent). A separate clinical evidence base supports efficacy in generalized anxiety disorder, with randomized placebo-controlled trials demonstrating superiority on the Hamilton Anxiety Rating Scale and comparable efficacy to escitalopram with superior sleep restoration.

    Pharmacokinetics are dominated by extensive hepatic first-pass metabolism through cytochrome P450 1A2 (CYP1A2, accounting for approximately 90 percent of clearance) and CYP2C9/CYP2C19 (approximately 10 percent), producing an oral bioavailability of approximately 1 percent despite greater than 80 percent gastrointestinal absorption, a plasma elimination half-life of 1 to 2 hours, and high inter-individual variability driven principally by CYP1A2 activity. The major metabolites (3-hydroxy-agomelatine, 7-desmethyl-agomelatine, and 3-hydroxy-7-desmethyl-agomelatine) are pharmacologically inactive and are renally eliminated after conjugation. CYP1A2 induction by tobacco smoking reduces plasma concentrations three- to fourfold; strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) increase exposure by up to 60-fold and are contraindicated in concurrent use.

    The principal safety concern specific to agomelatine is dose-dependent hepatotoxicity, manifesting as transaminase elevation greater than three times the upper limit of normal in approximately 1.3 percent of patients at 25 mg daily and 2.5 percent at 50 mg daily. Serious hepatic reactions including cytolytic hepatitis and rare hepatic failure have been reported in postmarketing surveillance. Regulatory authorities require liver function testing before treatment initiation, at approximately 3, 6, 12, and 24 weeks of treatment, and at dose increase. Withdrawal of agomelatine leads to rapid normalization of transaminases in essentially all reported cases. The compound is contraindicated in patients with hepatic impairment.

    This monograph reviews the chemistry, synthesis, and structural pharmacology of agomelatine; the dual-receptor mechanism in molecular and circadian detail; the comprehensive human pharmacokinetic record including CYP1A2 polymorphism and drug interactions; the clinical evidence base across major depressive disorder, generalized anxiety disorder, and sleep-related indications; the preclinical pharmacology including circadian, neurogenic, and anti-stress mechanisms; sourcing and quality verification for research applications; reconstitution and handling; stack-interaction considerations; the hepatotoxicity signal and broader adverse-event profile; and a comparative assessment of five alternative compounds (melatonin, ramelteon, tasimelteon, mirtazapine, vortioxetine) against agomelatine on five competency standards. The compound is not approved by the United States Food and Drug Administration. It is sold as a research-grade preparation outside its marketed antidepressant application; investigators should obtain analytical confirmation of identity and purity on every lot.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-072Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • ABT-737

    Plain-language summaryIntrigue 50 / 100

    ABT-737 is the structural and pharmacological predecessor to navitoclax: same target profile (BCL-2, BCL-XL, BCL-W), same BH3-mimetic logic, same selective killing of senescent cells in animal models, but missing the modifications that made navitoclax orally bioavailable. So ABT-737 is a research-only compound, given by intraperitoneal injection in mouse studies and never developed for clinical use. It remains widely used in cancer biology and senolytic research as a comparator for newer BCL-2 family inhibitors and as a tool to probe BH3-mimetic biology in cell lines and primary cells. Of historical interest as the original molecule that established the senolytic potential of the BCL-2 family. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    BH3 mimetic inhibitor of anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-xL, Bcl-w)

    A potent, cell-permeable BH3-mimetic small molecule developed at Abbott Laboratories by fragment-based drug design, capable of high-affinity binding to the hydrophobic groove of Bcl-2, Bcl-xL, and Bcl-w to displace pro-apoptotic BH3-only proteins and trigger Bak/Bax-dependent mitochondrial apoptosis in Bcl-2-dependent tumor cells and senescent cells.

    Abstract

    ABT-737 is a rationally designed BH3 mimetic small molecule that binds with sub-nanomolar affinity (Ki less than 1 nM) to the BH3-binding groove of the anti-apoptotic proteins Bcl-2, Bcl-xL, and Bcl-w, displacing sequestered pro-apoptotic effectors (Bax, Bak) and BH3-only activators (Bid, Bim) to trigger the intrinsic mitochondrial apoptotic pathway [1]. Developed at Abbott Laboratories (now AbbVie) and reported by Oltersdorf et al. in 2005, ABT-737 was the product of a landmark structure-activity relationships by nuclear magnetic resonance (SAR-by-NMR) fragment-based drug discovery campaign in which two small-molecule fragments identified by NMR chemical shift perturbation screening against Bcl-xL were chemically linked and iteratively optimized by parallel synthesis and X-ray crystallography-guided design to yield a compound approximately three orders of magnitude more potent than any prior Bcl-2 family inhibitor [1, 2]. The compound binds weakly (Ki greater than 460 nM) to the structurally related anti-apoptotic proteins Mcl-1 and Bfl-1/A1, a selectivity gap that defines both the therapeutic window and the principal resistance mechanism observed across tumor models.

    In preclinical studies, ABT-737 demonstrated potent single-agent antitumor activity in xenograft models of small-cell lung cancer (SCLC), follicular lymphoma, and chronic lymphocytic leukemia (CLL), producing complete tumor regressions in SCLC models derived from H146 and H187 cell lines and inducing rapid apoptosis in primary CLL cells at an EC50 of approximately 7 nM [1, 3, 4]. Activity extends to acute myeloid leukemia (AML) blasts and leukemia stem cells, multiple myeloma cell lines with Bcl-2 dependence, and several solid tumor models in combination with conventional chemotherapy or targeted agents [5, 6, 7]. The compound preferentially induces apoptosis in malignant cells while showing reduced activity against normal hematopoietic progenitors at equivalent concentrations, a selectivity attributed to the elevated Bcl-2 dependence of transformed cells relative to their normal counterparts.

    A critical limitation of ABT-737 is its lack of oral bioavailability and poor aqueous solubility, properties that confined it to parenteral administration in preclinical models and precluded direct clinical development [1]. These pharmacokinetic constraints motivated the subsequent design of navitoclax (ABT-263), an orally bioavailable analog with equivalent target selectivity, and ultimately venetoclax (ABT-199), a Bcl-2-selective derivative that eliminated the dose-limiting thrombocytopenia caused by Bcl-xL inhibition in platelets [8, 9]. Venetoclax received FDA approval in 2016 for CLL and subsequently for AML, validating the therapeutic hypothesis that ABT-737 established preclinically.

    Beyond oncology, ABT-737 has been characterized as a senolytic agent capable of selectively clearing senescent cells through disruption of the Bcl-2/Bcl-xL-dependent survival program that senescent cells upregulate as part of the senescence-associated anti-apoptotic phenotype (SAAP) [10]. Administration of ABT-737 during the second half of life in progeroid mouse models abrogated senescence markers and increased median survival, extending the compound’s research relevance to aging biology, fibrosis, and tissue regeneration [10, 11].

    This monograph documents the chemistry, synthesis, and fragment-based discovery of ABT-737; the molecular pharmacology of BH3-groove binding and Bak/Bax activation; pharmacokinetic properties and in vivo dosing; the preclinical evidence base across hematologic malignancies, solid tumors, and senescence; sourcing and quality verification considerations; reconstitution and handling; stack interactions and combination strategies; the adverse-event and safety signal (principally Bcl-xL-mediated thrombocytopenia); and a structured comparative assessment of five BH3 mimetic and Bcl-2 family inhibitors (navitoclax, venetoclax, obatoclax, S63845, and AT-101) against ABT-737 on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-299Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • 7-Hydroxymitragynine

    Plain-language summaryIntrigue 60 / 100

    7-Hydroxymitragynine is the more potent mu-opioid agonist alkaloid in kratom and is also a metabolite of mitragynine. It is sold as a concentrated alkaloid product with greater opioid activity than whole kratom. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Terpenoid indole alkaloid with mu-opioid receptor partial agonism and G-protein biased signaling

    A potent oxidative metabolite of mitragynine from Mitragyna speciosa (kratom) distinguished by mu-opioid receptor partial agonism with G-protein biased signaling, oral analgesic activity exceeding morphine potency, and an emerging regulatory landscape reflecting both therapeutic promise and abuse liability.

    Abstract

    7-Hydroxymitragynine (7-OH) is a terpenoid indole alkaloid isolated from the leaves of Mitragyna speciosa Korth. (kratom), first characterized by Ponglux, Takayama, and colleagues in 1994 as a minor constituent comprising less than 2 percent of the total alkaloid content of Thai kratom leaf material [1]. The compound is the C7-hydroxylated derivative of mitragynine, the principal alkaloid of kratom, and is generated both as a natural biosynthetic product in the plant and as a hepatic metabolite of mitragynine through cytochrome P450 3A (CYP3A) isoform-mediated oxidation in mammalian systems [2, 3]. 7-Hydroxymitragynine binds the mu-opioid receptor (MOR) with high affinity (Ki approximately 7 to 70 nM depending on the assay system and radioligand employed), approximately 5- to 46-fold greater than mitragynine, and produces antinociception in rodent hot-plate and tail-flick models at potencies approximately 13-fold greater than morphine on a weight basis after subcutaneous administration and with superior oral bioactivity [4, 5]. The compound functions as a partial agonist at the mu-opioid receptor, with G-protein biased signaling that results in minimal recruitment of beta-arrestin-2, a downstream effector linked to opioid-induced respiratory depression, constipation, and tolerance in the beta-arrestin hypothesis of opioid pharmacology [6, 7]. At delta-opioid (DOR) and kappa-opioid (KOR) receptors, 7-hydroxymitragynine acts as a competitive antagonist, a selectivity profile that distinguishes it from classical full opioid agonists such as morphine and fentanyl [8].

    The pharmacokinetic profile of 7-hydroxymitragynine in humans has been characterized in healthy volunteer studies of oral kratom administration. Maximum plasma concentrations are achieved approximately 1.2 to 2.0 hours after ingestion, with an elimination half-life of approximately 2.5 to 5 hours after single dosing that extends to approximately 24 hours with repeated administration [9, 10]. The compound is formed hepatically from mitragynine through CYP3A4-mediated oxidation; co-administration of the CYP3A4 inhibitor itraconazole reduces 7-hydroxymitragynine Cmax by approximately 56 percent and AUC by 43 percent while increasing mitragynine exposure 1.5-fold, confirming the CYP3A4 dependence of the metabolic conversion [10]. Preclinical studies demonstrate that chronic administration of 7-hydroxymitragynine produces opioid-type physical dependence, tolerance, and naloxone-precipitated withdrawal in mice, with cross-tolerance to morphine [11]. Respiratory depression occurs at potencies approximately 3-fold greater than morphine, though the ceiling effect characteristic of partial agonism may limit the magnitude of respiratory suppression relative to full agonists at equianalgesic doses [12].

    The regulatory landscape for 7-hydroxymitragynine is rapidly evolving. In July 2025, the United States Food and Drug Administration recommended that the Drug Enforcement Administration schedule synthetic and concentrated 7-hydroxymitragynine as a Schedule I controlled substance, while indicating that natural kratom leaf products are not the focus of the scheduling recommendation [13]. Several U.S. states, including Florida, Louisiana, Mississippi, and Colorado, have independently scheduled concentrated 7-hydroxymitragynine products [13]. The compound is not approved for any therapeutic indication in any jurisdiction. This monograph reviews the chemistry, biosynthesis, and semisynthesis of 7-hydroxymitragynine; the opioid receptor pharmacology with emphasis on biased signaling; the human and animal pharmacokinetic record; the preclinical analgesic, tolerance, and dependence evidence; the limited clinical and epidemiological data; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse events and safety signals; and a comparative assessment of five kratom-derived or structurally related opioid analgesic candidates against 7-hydroxymitragynine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-156Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Abaloparatide

    Plain-language summaryIntrigue 58 / 100

    Abaloparatide, sold as Tymlos, is a modified analog of parathyroid hormone-related protein (a relative of PTH) with substitutions at nine positions designed to make it bind the PTH1 receptor with selectivity for the transient signaling state. The functional consequence is more anabolic and less catabolic effect compared to teriparatide, theoretically offering better bone formation with less bone resorption. Head-to-head ACTIVE trial data showed similar fracture reduction to teriparatide with a different side effect profile. Approved by the FDA in 2017, it occupies the same niche as teriparatide for severe osteoporosis. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Synthetic parathyroid hormone-related protein (PTHrP) analog and selective PTH1 receptor agonist with preferential RG-conformation binding

    A 34-amino-acid synthetic analog of human parathyroid hormone-related protein (1-34) engineered for selective activation of the RG conformation of the PTH type 1 receptor, producing transient osteoanabolic cAMP signaling with reduced bone resorption and hypercalcemia relative to teriparatide, approved for the treatment of osteoporosis in postmenopausal women and men at high fracture risk.

    Abstract

    Abaloparatide (BA058) is a synthetic 34-amino-acid peptide analog of human parathyroid hormone-related protein (PTHrP) (1-34) that acts as a selective agonist at the parathyroid hormone type 1 receptor (PTH1R), a class B G protein-coupled receptor expressed on osteoblasts and osteocytes. The compound was rationally designed to exploit conformational selectivity at PTH1R: abaloparatide binds the G protein-coupled RG conformation with an IC50 of approximately 0.20 nM and the G protein-independent R0 conformation with an IC50 of approximately 316 nM, yielding a 1,600-fold RG/R0 selectivity ratio that exceeds native PTHrP(1-36) (110-fold), native PTH(1-34) (12-fold), and the long-acting analog LA-PTH (2.2-fold). This selectivity produces a transient downstream cAMP signaling response following receptor activation, which, when delivered as a once-daily intermittent subcutaneous injection, preferentially stimulates osteoblast-mediated bone formation with lesser stimulation of osteoclast-mediated bone resorption and a lower incidence of hypercalcemia than teriparatide (recombinant PTH(1-34)), the first-in-class parathyroid hormone receptor agonist for osteoporosis.

    The compound shares 76% amino acid sequence homology with native PTHrP(1-34) and 41% homology with native PTH(1-34). The first 22 amino acids are identical to PTHrP(1-22); positions 23 through 34 carry eight substitutions, including an alpha-aminoisobutyric acid (Aib) residue at position 29, introduced to constrain the C-terminal alpha-helix and enhance peptide stability and receptor binding selectivity. The molecular formula is C174H300N56O49 with a molecular weight of approximately 3,960 daltons. The compound is administered as a once-daily 80 microgram subcutaneous injection into the periumbilical abdominal region. Pharmacokinetics after subcutaneous dosing are characterized by rapid absorption (median Tmax approximately 0.51 hours), an absolute bioavailability of approximately 36%, a volume of distribution of approximately 50 liters, plasma protein binding of approximately 70%, and an elimination half-life of approximately 1 hour, with clearance proceeding through nonspecific proteolytic degradation to smaller peptide fragments followed by renal excretion.

    Clinical efficacy was established in the pivotal ACTIVE trial (Abaloparatide Comparator Trial In Vertebral Endpoints), an 18-month, international, randomized, double-blind, placebo- and active-controlled Phase 3 study in 2,463 postmenopausal women with osteoporosis, in which abaloparatide 80 microgram daily reduced the risk of new morphometric vertebral fractures by 86% relative to placebo (0.58% versus 4.22%) and nonvertebral fractures by 43% (2.7% versus 4.7%). The subsequent ACTIVExtend trial demonstrated that sequential treatment with abaloparatide followed by alendronate maintained fracture risk reduction and further increased bone mineral density over a combined 43-month observation period. The ATOM trial extended efficacy to men with osteoporosis, demonstrating lumbar spine bone mineral density gains of 8.48% versus 1.17% on placebo at 12 months. The compound received United States Food and Drug Administration approval on April 28, 2017, for postmenopausal women with osteoporosis at high fracture risk (marketed as Tymlos), with an expanded indication for men with osteoporosis approved in December 2022. European Medicines Agency approval was granted in December 2022 under the trade name Eladynos. A transdermal solid microstructured transdermal system (sMTS) formulation is in clinical development as an alternative to subcutaneous injection. Treatment duration is limited to a cumulative lifetime maximum of 2 years owing to a dose- and time-dependent increase in osteosarcoma incidence observed in preclinical rodent carcinogenicity studies, a class effect shared with teriparatide.

    This monograph reviews the chemistry, synthesis, and structural pharmacology of abaloparatide; the molecular mechanism of PTH1R conformational selectivity and downstream signaling; comprehensive pharmacokinetics; preclinical pharmacology in ovariectomized and orchiectomized rodent models; the clinical evidence base across the ACTIVE, ACTIVExtend, and ATOM trials; sourcing and quality verification for research applications; reconstitution and handling; stack-interaction considerations; the adverse-event and safety profile including the osteosarcoma signal and cardiovascular safety analysis; and a structured comparative assessment of five alternative bone-active agents (teriparatide, romosozumab, denosumab, zoledronic acid, and raloxifene) against abaloparatide on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-367Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Agmatine

    Plain-language summaryIntrigue 55 / 100

    Agmatine is a naturally occurring small molecule made in the body from arginine. It modulates several systems including NMDA receptors, nitric oxide, and imidazoline receptors. Used as a supplement for nerve pain and mood. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Endogenous polyamine neuromodulator with multi-target activity at NMDA receptors, imidazoline receptors, alpha-2 adrenoceptors, and nitric oxide synthase

    A decarboxylated arginine metabolite and endogenous neuromodulator distinguished by concurrent NMDA receptor channel blockade, imidazoline receptor agonism, selective inducible nitric oxide synthase inhibition, and alpha-2 adrenoceptor activation, with emerging clinical evidence in neuropathic pain, depression, and neuroprotection.

    Abstract

    Agmatine (4-aminobutylguanidine) is an endogenous cationic amine produced by the decarboxylation of L-arginine via the mitochondrial enzyme arginine decarboxylase. First isolated in 1910 by the Nobel laureate Albrecht Kossel from herring sperm protamine hydrolysates, agmatine was rediscovered in 1994 as an endogenous mammalian neuromodulator synthesized, stored in synaptic vesicles, and released in a calcium-dependent manner from neurons in the hippocampus, hypothalamus, locus coeruleus, and other brain regions. The compound operates through a pharmacologically unusual multi-target profile: it produces voltage-dependent blockade of NMDA receptor-gated cation channels at an intrachannel pore site (IC50 approximately 300 micromolar); it binds with high affinity to imidazoline I1 receptors (Kd approximately 0.7 micromolar) and I2 receptors (Kd approximately 1 micromolar); it activates alpha-2 adrenoceptors (Kd approximately 4 micromolar); and it competitively inhibits inducible nitric oxide synthase (Ki approximately 220 micromolar) with selectivity over the neuronal and endothelial isoforms. This composite mechanism produces neuroprotective, analgesic, antidepressant, and anti-inflammatory activity across a broad range of preclinical models, including excitotoxic and ischemic neuronal injury, traumatic brain injury, neuropathic and inflammatory pain, and behavioral models of depression and anxiety.

    Clinical evidence, though still early-phase and limited in scale, has demonstrated efficacy of oral agmatine sulfate in lumbar disc-associated radiculopathy in a randomized, double-blind, placebo-controlled trial at 2,670 mg per day for 14 days, with statistically significant pain reduction versus placebo [1]. A pilot open-label case series in painful small fiber neuropathy reported approximately 46 percent mean pain reduction over two months at the same dose [2]. A 2026 prospective open-label case series at Massachusetts General Hospital reported preliminary evidence for agmatine sulfate augmentation in treatment-resistant obsessive-compulsive disorder, with 40 percent of patients achieving clinically meaningful improvement on the Yale-Brown Obsessive Compulsive Scale [3]. Preclinical antidepressant-like activity has been demonstrated in the forced swimming test and tail suspension test across multiple laboratories, mediated through NMDA receptor blockade, nitric oxide synthase inhibition, and AMPA receptor and mTOR signaling activation. The compound modulates opioid pharmacology in a biphasic manner: it potentiates acute morphine analgesia while preventing the development of analgesic tolerance and physical dependence, a profile that has attracted substantial research interest in the context of the opioid crisis.

    Safety data are favorable. A long-term safety case report documented 5 years of continuous daily intake at 2.67 g agmatine sulfate with no adverse events, and postmarketing surveillance of 1,015 individuals consuming the same regimen for periods of 3 weeks to 3 years identified no adverse events [4]. Clinical trial adverse events have been limited to mild, transient gastrointestinal symptoms (nausea, diarrhea, abdominal discomfort) at the highest studied doses. The compound is commercially available as a dietary supplement (agmatine sulfate) in multiple jurisdictions. This monograph reviews the chemistry, biosynthesis, and multi-target pharmacology of agmatine; the pharmacokinetic profile including oral bioavailability and CNS distribution; the preclinical and clinical evidence base across neuropathic pain, depression, neuroprotection, and opioid modulation; sourcing and quality considerations; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five mechanistically related compounds against agmatine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-075Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Amantadine

    Plain-language summaryIntrigue 60 / 100

    Amantadine started life in 1968 as an oral antiviral for influenza A and was later discovered to help Parkinson disease patients, an entirely accidental finding that led to its current main role. It works through several mechanisms at once: weak NMDA glutamate receptor blockade (similar to memantine), dopamine release, and dopamine reuptake inhibition. Today it is most useful for the involuntary movements (dyskinesias) that develop after years of L-DOPA therapy, and for cognitive recovery after traumatic brain injury where it has the strongest evidence base of any drug. The flu indication has largely been abandoned because of widespread viral resistance. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Adamantane-derived multi-target neurotherapeutic agent with weak NMDA receptor antagonism, sigma-1 receptor agonism, and indirect dopaminergic activity

    A tricyclic adamantane amine originally developed as an influenza A antiviral, subsequently repositioned for Parkinson’s disease and levodopa-induced dyskinesia, distinguished by a polypharmacological profile spanning NMDA receptor antagonism, sigma-1 receptor agonism, dopaminergic facilitation, and nicotinic acetylcholine receptor modulation.

    Abstract

    Amantadine (1-adamantanamine) is a small-molecule adamantane derivative that has undergone three distinct phases of clinical development since its original synthesis in the 1960s: as the first synthetic antiviral agent active against influenza A virus through blockade of the M2 ion channel protein; as an antiparkinsonian agent discovered serendipitously in 1968 and subsequently approved for the treatment of drug-induced extrapyramidal reactions and as adjunctive therapy in Parkinson’s disease; and, most recently, as a delayed-release and extended-release formulation (Gocovri) approved by the United States Food and Drug Administration in 2017 for the treatment of levodopa-induced dyskinesia in Parkinson’s disease. The compound occupies a distinctive position in clinical neuropharmacology by virtue of a polypharmacological profile that engages multiple molecular targets at therapeutically relevant concentrations. At the N-methyl-D-aspartate (NMDA) receptor, amantadine acts as a weak, non-competitive, open-channel blocker that accelerates channel closure during channel block, producing glutamatergic modulation at concentrations achievable with standard oral dosing. At the sigma-1 receptor, amantadine acts as an agonist with a Ki of approximately 7.44 micromolar, a mechanism that has been linked to the modulation of dopaminergic neurotransmission including enhancement of tyrosine hydroxylase activity, facilitation of striatal dopamine release, and inhibition of dopamine reuptake. The compound also functions as a negative allosteric modulator of alpha-4-beta-2 and alpha-7 nicotinic acetylcholine receptors, with IC50 values in the low-micromolar range, and exerts additional effects on potassium channels, aromatic amino acid decarboxylase, and glial-cell-derived neurotrophic factor expression.

    The clinical evidence base for amantadine now spans six decades and includes approved indications in Parkinson’s disease (both as monotherapy for mild symptoms and as adjunctive therapy for levodopa-induced dyskinesia), drug-induced extrapyramidal reactions, and influenza A prophylaxis and treatment (now largely obsolete owing to widespread viral resistance). Off-label applications with meaningful clinical support include acceleration of functional recovery in traumatic brain injury with disorders of consciousness, as demonstrated in the landmark Giacino et al. (2012) randomized placebo-controlled trial published in the New England Journal of Medicine; management of fatigue in multiple sclerosis; and reduction of chorea in Huntington disease. Pharmacokinetics are characterized by high oral bioavailability (86 to 90 percent), minimal hepatic metabolism with predominantly renal excretion of unchanged drug, a plasma elimination half-life of approximately 12 hours in subjects with normal renal function (extending to 7 to 10 days in severe renal impairment), and the absence of significant cytochrome P450 involvement. The adverse-event profile includes central nervous system effects (insomnia, dizziness, hallucinations, confusion), peripheral edema, the distinctive dermatological finding of livedo reticularis, and, at supratherapeutic doses or in overdose, QT prolongation and cardiac arrhythmias. This monograph reviews the chemistry, synthesis, and structural class of amantadine; the multi-target molecular pharmacology in mechanistic detail; comprehensive pharmacokinetics; the clinical evidence base across all approved and investigational indications; sourcing, reconstitution, and handling considerations for laboratory work; stack-interaction implications; adverse-event signal; and a comparative assessment of five alternative agents (memantine, rimantadine, budipine, safinamide, and istradefylline) against amantadine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-319Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.